Spectranetics Takes CLiRpath To 510(k) Clearance For Leg Artery Occlusions
This article was originally published in The Gray Sheet
Executive Summary
Spectranetics will support a U.S. clinical trial for expanded use of its CVX-300 excimer laser technology for heart attacks with incremental profits from CLiRpath leg artery occlusion treatment sales